NOT IN USE FinnGen Analysis Proposal Form NOT IN USE

***THIS FORM IS NO LONGER IN USE***

THE NEW ANALYSIS PROPOSAL FORM IS AT: https://docs.google.com/forms/d/e/1FAIpQLSc0J0bpEWB_xvbsf7GAWML0Uhk_5DDCgyUCg20lDi-E4z6wWQ/viewform

THE NEW ANALYSIS PROPOSAL VIEWER APPSHEET IS AT: https://www.appsheet.com/start/ea608933-2713-4eec-a08e-b06703fb0ea1

Please note that a FinnGen account is required to access the new analysis proposals form and the new analysis proposals Viewer.

BEFORE you fill-in the proposal, please check the list of approved FinnGen analysis proposals for possible overlapping proposals.

In case your analysis plan is identical/similar to an already approved proposal, you may contact the key investigator of the proposal for collaboration.

Please contact finngen-admin@helsinki.fi if you have any questions or concerns about the new templates or the process.

Publication type

Based on FinnGen publication policy I am proposing

1. Primary analysis (eg. core analysis involving significant amount of FinnGen data and work of FinnGen core teams).

2. Secondary analysis (eg. indepth analysis of one disease or trait).

3. Analysis where FinnGen results are used in a peripheral way (replication studies and variant lookups).

Detailed description of the FinnGen publication policy Tiers (1.-3.) can be found from FinnGen members' area. Login using your finngen.fi credentials. If you don't have finngen.fi account, please contact: finngen-admin@helsinki.fi

Title and field

Title of the analysis

Disease or trait studied

Medical speciality (by FinnGen Clinical Task Forces)

If you chose 'Other', please describe.

Investigators

Key Investigator (affiliation to a FinnGen partner organization required)

Email Address

Affiliation

Key Investigator's FinnGen Partner Organization ?

Other investigators

	Name	email	Affiliation
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

Abstract

Abstract ?

NB. The abstract needs to include overall hypothesis, aims and analysis design, including methods and FinnGen data used (as detailed as possible).

Target journal

Target publication date

Analysis type

FinnGen Data Release used

Custom GWAS of a phenotype not available as a FinnGen core endpoint

PheWAS of a specific variant(s)

Rare variant analysis

Look at longitudinal phenotype data (development of phenotype over time)

Analyze detailed medication usage

Other

If you chose 'Other', please give more details

Please indicate do you need to use EA3 data in the analyses

Additional clinical data from some of the Expansion Area (EA3) studies is also available in the Sandbox. However, EA3 data is to be used only as stated in the respective EA3 study plan and needs to be discussed separately with the EA3 study group and FinnGen admin team. Please see more details in the Analyst handbook: Expansion Area (EA3) studies.

I will analyze individual level FinnGen data in Sandbox ?

If yes, indicate the name(s) of the person(s) performing the analyses in FinnGen Sandbox

	Name	email	Affiliation	@finngen.fi account user name
1.
2.
3.
4.
5.

Is the analysis part of a meta-analysis?

If your analysis is part of a meta-analysis, please give more details (e.g. reference to the consortium).

Overlapping FinnGen studies

Please check the list of FinnGen analysis proposals for possible overlapping FinnGen studies (link to FinnGen Sharepoint). In case your plan is identical/similar to an already approved proposal, you may contact the key investigator of the proposal for collaboration. FinnGen tries to avoid overlapping efforts.

I confirm that I have checked for overlapping proposals

Describe what other analyses in the same field is ongoing in FinnGen

Results sharing

All FinnGen research must adhere to the FinnGen Scientific Plan and its amendments. Please familiarize yourself to the FinnGen Scientific Plan and its amendment before submitting this proposal. FinnGen data is allowed to be used only for research determined in the Scientific Plan.

All analyses done using FinnGen data must also have articulated scientific purpose and potential to produce publishable results.

FinnGen analysis results are subjected to a one year embargo or “exclusivity period” for FinnGen Partners and only after that can be made available to the larger scientific community. This is described in the FinnGen Consortium Agreement signed by all FinnGen Partner organizations. The embargo is defined as the period of 12 months after each Data Freeze has been released to the FinnGen Partners. Data Freezes and data releases are done twice a year. During the embargo period, the analysis results are available only to FinnGen Partner organizations. These analysis results may be published as a part of a manuscript / abstract / poster, but the FinnGen Scientific Committee must first approve the release of these results, following similar practices as the Citing FinnGen. Access the links by login in to the FinnGen members' area. Log in using your finngen.fi credentials. If you don't have finngen.fi account contact: finngen-admin@helsinki.fi.

Once your proposal have been approved and you have finalized the analysis, please contact finngen-admin@helsinki.fi for guidance on how to share the results and acknowledge FinnGen in the publication. Note also that the final manuscript needs to be circulated to the FinnGen Scientific Committee (please reserve three weeks for the internal review process before submission)

Will public sharing of FinnGen results be required ?

If you chose 'Yes', please describe the time frame when you will share the results with FinnGen Partners ?

I am aware that

FinnGen is a research project and all analyses must have scientific purpose and potential to be published.

The final results shall be shared with the FinnGen Partners (once final).

The final manuscript shall be shared with the FinnGen Scientific Committee.

For meta-analyses, summary stats w/ and w/o FinnGen results shall be shared with FinnGen Partners (once ready).

All analyses using FinnGen individual level data is used to achieve FinnGen scientific plan goals, upon a positive decision by FinnGen Partners.

Anonymized results might be used for collaborative studies where they are combined with results from other studies.

There is 12 mo embargo for the FinnGen data and only after that the results can be made available to the larger scientific community.

All individuals listed have agreed to be part of the proposal.

You understand you take on the responsibility for project analysis with the staff listed on the application. FinnGen core team does NOT provide custom analysis service, though of course the approved project gives you access to the required IT support needed to execute it - if you need analysis help you should identify a partner beforehand.

Proceed

If you have any questions or concerns regarding your application, please contact finngen-admin@helsinki.fi